[1]
Conese M. Cystic fibrosis and the innate immune system: therapeutic implications. Endocr Metab Immune Disord Drug Targets 2011; 11: 8-22.
[2]
Colombo C, Faelli N, Tirelli S, et al. Conese M. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cysticfibrosis. Int J Immunopathol Pharmacol 2011; 24: 423-32.
[3]
Conese M. Ascenzioni F., Boyd A.C., Coutelle C., De Fino I., De Smedt S., Rejman J., Rosenecker J., Schindelhauer D., Scholte B.J. Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros 2011; 10 (Suppl. 2): S114-28.
[4]
Becq F, Mall MA, Sheppard DN. Conese M., Zegarra-Moran O. Pharmacological therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros 2011; 10 (Suppl. 2): S129-45.
[5]
Piro D, Piccoli C, Guerra L, et al. Conese M. Hematopoietic stem/progenitor cells express functional mitochondrial energy dependent cystic fibrosis trans membrane conductance regulator. Stem Cells Dev 2012; 21(4): 634-46.
[6]
Paracchini V, Carbone A, Colombo F, et al. Conese M. Amniotic mesenchymal stem cells: A new source for hepatocyte-like cells and induction of CFTR expression by co-culture with cystic fibrosis airway epithelial cells. Journal ofBiomedicine and Biotechnology 2012; 2012: 575471.
[7]
Montemurro P, Mariggiò MA, Barbuti G, et al. Conese M. Increase in interleukin-8 production from circulating neutrophils upon antibiotic therapy in cystic fibrosis. J Cyst Fibros 2012; 11: 518-24.
[8]
Castellani S, Guerra L, Favia M, Di Gioia S, Casavola V, Conese M. NHERF1 and CFTR restore tight junction organisationand function in cystic fibrosis airway epithelial cells: role of ezrin and the RhoA/ROCK pathway. Lab Invest 2012; 92: 1527-40.